Ebanel Bio Drying Lotion
Everything behind the verdicts on this product: the rule that fired for each concern, the three answers and the documents they rest on, every study on the row with the date it was opened, and the versions of the tables that produced them. Nothing here is edited by hand; it is generated from the same records the verdicts are.
The scaleRecommendedGoodSupportingEarly evidenceNot for thisAvoidhow it works
Engine 5.2.0 · rules 0.5.1 · evidence table ev-2026.10-r231 · computed October 13, 2026 · how we decide · the evidence table · the anchors
for Acne
Sulfur is an approved or monograph active for acne; this liquid carries it, though the concentration is not declared.
A first-line active — approved, monograph-listed or named in current guidelines — at an effective strength, with no trigger for the concern.
- Rule
- R3 → Strong choice. A first-line active (approved, monograph-listed or named in a current guideline); at a plausible but undeclared level.
q1 = first-line · q2 = plausible
Why this rule exists: Undeclared but plausibly dosed (top-third INCI position, or a potent sub-1% active) — the verdict stands, and the sentence says what disclosure would add. A declared figure below range would have been sub-threshold.
Rule R3 decided 570 verdicts across the catalog; “Strong choice” is the verdict on 1,475 of 45,446. The full register. - Carrying active
- Sulfur
- 1 · Standing
- First-line — a regulator recognises it for this use; trials support it
Document: § 333.310 Acne active ingredients. (U.S. Food and Drug Administration — 21 CFR Part 333 Subpart D (Topical Acne Drug Products), Code of Federal Regulations via GovInfo), opened July 27, 2026 - 2 · Form
- Plausible — concentration not declared; read from the position in the ingredient list
Studied range: 3–10%, from the OTC monograph or label - 3 · Tolerability
- Standard tolerability — irritant load
Cautions: known irritants. - Evidence dots
- Limited evidence
Row checked against its sources on July 27, 2026 (evidence table ev-2026.10-r231). - What readers report
- No reviews read yet for this product. Shown beside the verdict; never blended into it.
- Verdict since
- September 5, 2026 (unchanged across rebuilds since then)
The studies and documents on the row
- Guidelines of care for the management of acne vulgaris (Reynolds et al.) — Journal of the American Academy of Dermatology — AAD clinical guideline, 2024;90(5):1006.e1-1006.e30, doi:10.1016/j.jaad.2023.12.017, PMID 38300170 (2024), opened July 17, 2026
← Back to the verdict All acne products → Disclose a concentration or correct a fact →
for Blackheads
Salicylic Acid is an approved or monograph active for blackheads; this liquid carries it, though the concentration is not declared.
A first-line active — approved, monograph-listed or named in current guidelines — at an effective strength, with no trigger for the concern.
- Rule
- R3 → Strong choice. A first-line active (approved, monograph-listed or named in a current guideline); at a plausible but undeclared level.
q1 = first-line · q2 = plausible
Why this rule exists: Undeclared but plausibly dosed (top-third INCI position, or a potent sub-1% active) — the verdict stands, and the sentence says what disclosure would add. A declared figure below range would have been sub-threshold.
Rule R3 decided 570 verdicts across the catalog; “Strong choice” is the verdict on 1,475 of 45,446. The full register. - Carrying active
- Salicylic Acid
- 1 · Standing
- First-line — a regulator recognises it for this use; trials support it
Document: 21 CFR § 333.350 - Labeling of acne drug products. (US Code of Federal Regulations (Legal Information Institute, Cornell Law School)), opened July 27, 2026 - 2 · Form
- Plausible — concentration not declared; read from the position in the ingredient list
Studied range: 0.5–2%, from the OTC monograph or label; judge it after about 6 weeks - 3 · Tolerability
- Standard tolerability
- Evidence dots
- Moderate evidence
Row checked against its sources on July 27, 2026 (evidence table ev-2026.10-r231). - What readers report
- No reviews read yet for this product. Shown beside the verdict; never blended into it.
- Verdict since
- September 5, 2026 (unchanged across rebuilds since then)
The studies and documents on the row
- OTC monograph, Topical Acne Drug Products — salicylic acid 0.5–2% recognized as an acne treatment active — US Food and Drug Administration
- 2% supramolecular salicylic acid hydrogel vs. adapaline gel in mild to moderate acne vulgaris treatment: A multicenter, randomized, evaluator-blind, parallel-controlled trial — Journal of Cosmetic Dermatology (2024), opened July 17, 2026
← Back to the verdict All blackheads products → Disclose a concentration or correct a fact →
for Excess Oiliness
Salicylic Acid has trial-level evidence for excess oiliness but no guideline or regulatory standing yet — promising, short of a recommendation; the other actives here are not yet assessed for it.
The lead active has at least one trial behind it for the concern but no guideline or regulatory standing yet, and is present at a working level. Short of a recommendation.
- Rule
- R9p → Promising. An active with early or mechanistic evidence only; declared at a working strength, or a labelled active or at a plausible but undeclared level; the product’s category job is not a recognised companion to the concern; moderate or strong evidence dots on the carrier’s row.
q1 = plausible · q2 = adequate | plausible · supportive = false · strength = moderate | strong
Why this rule exists: 0.5.0: 'Unproven' beside three filled dots read as one question answered twice with opposite words (7,018 rows). The chip measures standing, the dots measure trial volume; where the row carries at least one RCT or a tier-2 source (moderate dots) and the active is present at a working level, the honest word is Promising. Unproven is reserved for plausible-standing rows with limited or weak evidence, or an under-dosed form. Same rank as Unproven — a bet either way; the dots order them.
Rule R9p decided 4,872 verdicts across the catalog; “Promising” is the verdict on 4,872 of 45,446. The full register. - Carrying active
- Salicylic Acid
- 1 · Standing
- Plausible — trials support it
- 2 · Form
- Plausible — concentration not declared; read from the position in the ingredient list
- 3 · Tolerability
- Standard tolerability
- Evidence dots
- Moderate evidence
- What readers report
- No reviews read yet for this product. Shown beside the verdict; never blended into it.
- Verdict since
- September 5, 2026 (unchanged across rebuilds since then)
The studies and documents on the row
- 30% Supramolecular Salicylic Acid Improved Symptoms and Skin Barrier in Papulopustular Rosacea — Journal of Cosmetic Dermatology — TRUE vehicle (matrix minus SA); investigator-initiated, China Medical University, no declared conflicts (2025), opened July 16, 2026
- Salicylic acid treats acne vulgaris by suppressing AMPK/SREBP1 pathway in sebocytes — Experimental Dermatology — in vitro SEB-1 sebocytes + rabbit ear; NO human data (2019), opened July 16, 2026
- Clinical Efficacy of a Salicylic Acid-Containing Gel on Acne Management and Skin Barrier Function: A 21-Day Prospective Study — Journal of Cosmetic Dermatology — SINGLE-ARM, not an RCT; L'Oréal/CeraVe-employed co-authors testing their own product; EXCLUDED, see notes (2025), opened July 16, 2026
- 30% supramolecular salicylic acid peels effectively treats acne vulgaris and reduces facial sebum — Journal of Cosmetic Dermatology — self-contrast, no control arm; EXCLUDED (2022), opened July 16, 2026
- Efficacy and safety of a facial serum and a mask containing salicylic acid and lipohydroxy acid in acne management: A randomized controlled trial — Journal of Cosmetic Dermatology — randomized, but BOTH arms received the SA serum (mask vs no mask); no vehicle arm; all authors L'Oréal China; EXCLUDED (2023), opened July 16, 2026
- 2% supramolecular salicylic acid hydrogel vs. adapaline gel in mild to moderate acne vulgaris treatment: A multicenter, randomized, evaluator-blind, parallel-controlled trial. — Journal of Cosmetic Dermatology — n=500, 16 weeks; sebum was MEASURED but the comparator is adapalene, not vehicle, and the abstract reports no sebum result; full text not in PMC. EXCLUDED (no vehicle arm; endpoint result unreported) (2024), opened October 13, 2026
← Back to the verdict All excess oiliness products → Disclose a concentration or correct a fact →
No category-job specification exists for this category yet, so there is no job reading.
- Known irritants
A verdict is Dermington’s assessment of how well a product’s ingredients fit a concern — never a claim about what the product treats. Every rule is public and the same for every product; a brand cannot buy a reading. How we decide · what has changed · disclaimer.